Clinical Trials Logo

Appendiceal Adenocarcinoma clinical trials

View clinical trials related to Appendiceal Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06399757 Not yet recruiting - Prostate Cancer Clinical Trials

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

NCT ID: NCT05947838 Recruiting - Colorectal Clinical Trials

A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma

Start date: December 4, 2023
Phase: N/A
Study type: Interventional

To learn if circulating tumor DNA (ctDNA) testing before cytoreductive surgery (CRS) with or without heated intraperitoneal chemotherapy (HIPEC) can show if patients have a low or high risk of the disease returning and help doctors decide if less or more intense chemotherapy is needed as treatment before surgery. ctDNA testing measures the amount of tumor DNA (genetic information) in the blood.

NCT ID: NCT05734430 Recruiting - Appendix Cancer Clinical Trials

Genetics of Appendix Cancer Study

GAP
Start date: November 11, 2022
Phase:
Study type: Observational

The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years.

NCT ID: NCT04665921 Terminated - Clinical trials for Colorectal Neoplasms

A Study of SGN-STNV in Advanced Solid Tumors

Start date: January 18, 2021
Phase: Phase 1
Study type: Interventional

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.